Caitong International Asset Management’s Royalty Pharma RPRX Stock Holding History

Caitong International Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$258K	Buy	+4,603	New	+$240K	0.04%	368
2026 Q1	–	Sell	-3,681	Closed	-$142K	–	2989
2025 Q4	$142K	Buy	3,681 +838	+29%	+$32K	0.03%	300
2025 Q3	$100K	Buy	+2,843	New	+$103K	0.07%	167
2025 Q2	–	Sell	-6,829	Closed	-$213K	–	2410
2025 Q1	$213K	Buy	+6,829	New	+$216K	0.16%	112

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caitong International Asset Management's RPRX Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 4,603 shares worth $258K. The stake represents 0.04% of the portfolio and ranks #368 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in RPRX as recently as Q4 2025.

Caitong International Asset Management first reported a position in RPRX in Q1 2025 and has held it in 4 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Caitong International Asset Management held 4,603 shares of Royalty Pharma worth $258K as of Q2 2026.
Royalty Pharma was a new Caitong International Asset Management position in Q2 2026.
Royalty Pharma made up 0.04% of Caitong International Asset Management's portfolio in Q2 2026, its #368 holding.
Caitong International Asset Management first reported a position in Royalty Pharma in Q1 2025 and has held it in 4 quarters since.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.